Cargando…

Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis

BACKGROUND AND AIMS: Bowel urgency and abdominal pain are impactful, yet under-appreciated ulcerative colitis symptoms and not commonly assessed in clinical trials. We evaluated how these symptoms may improve with upadacitinib treatment and correlate with clinical and health-related quality of life...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghosh, Subrata, Sanchez Gonzalez, Yuri, Zhou, Wen, Clark, Ryan, Xie, Wangang, Louis, Edouard, Loftus, Edward V, Panes, Julian, Danese, Silvio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684481/ https://www.ncbi.nlm.nih.gov/pubmed/34107013 http://dx.doi.org/10.1093/ecco-jcc/jjab099

Ejemplares similares

Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data
por: Danese, Silvio, et al.
Publicado: (2023)

Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results
por: Panés, Julian, et al.
Publicado: (2023)

Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn’s Disease
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2021)

Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy
por: Napolitano, Maria, et al.
Publicado: (2022)

Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission
por: Dubinsky, Marla C, et al.
Publicado: (2022)

A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY
por: Panaccione, R, et al.
Publicado: (2022)

A186 ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION
por: Clemow, D B, et al.
Publicado: (2023)

Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis
por: Ernest-Suarez, Kenneth, et al.
Publicado: (2023)

Bowel Urgency in Ulcerative Colitis: Current Perspectives and Future Directions
por: Dubinsky, Marla, et al.
Publicado: (2023)

Atopic Dermatitis and Ulcerative Colitis Successfully Treated with Upadacitinib
por: Grieco, Teresa, et al.
Publicado: (2023)

Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis
por: Dubinsky, Marla C, et al.
Publicado: (2022)

Exploring Disease Remission and Bowel Urgency Severity Among Adults with Moderate to Severe Ulcerative Colitis: A Qualitative Study
por: Dubinsky, Marla C, et al.
Publicado: (2022)

Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Ulcerative Colitis-Symptom Questionnaire: Valid for Use in Adults with Moderately to Severely Active Ulcerative Colitis
por: Panes, Julian, et al.
Publicado: (2023)

Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients
por: Ponce-Bobadilla, Ana Victoria, et al.
Publicado: (2022)

Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis
por: Solitano, Virginia, et al.
Publicado: (2020)

Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes
por: Irani, Malcolm, et al.
Publicado: (2023)

A case of nocardiosis in a patient with ulcerative colitis on chronic corticosteroids, infliximab, and upadacitinib
por: Moy, Benjamin M., et al.
Publicado: (2023)

Real‐world use of endoscopic and histological indices in ulcerative colitis: Results of a global survey
por: Nardone, Olga Maria, et al.
Publicado: (2023)

Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults
por: Dubinsky, Marla C., et al.
Publicado: (2022)

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
por: Caron, Bénédicte, et al.
Publicado: (2022)

Upadacitinib as a Rescue Therapy in Acute Severe Ulcerative Colitis: A Case Report and Review of the Literature
por: Ali, Nargess Mahmoud, et al.
Publicado: (2023)

Medically Refractory Lymphocytic Colitis Successfully Treated With Upadacitinib
por: Miyatani, Yusuke, et al.
Publicado: (2023)

Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme
por: Sandborn, William J., et al.
Publicado: (2019)

Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program
por: Sands, Bruce E, et al.
Publicado: (2021)

Assessment of the effectiveness of Budesonide MMX(®) for active, mild-to-moderate ulcerative colitis in the Polish sub-group of the CORE Practice prospective multi-centre observational study
por: Jesionowski, Maciej, et al.
Publicado: (2023)

Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
por: Danese, Silvio, et al.
Publicado: (2016)

A190 THE IMPACT OF BOWEL URGENCY ON THE LIVES OF PATIENTS WITH ULCERATIVE COLITIS IN THE US AND EUROPE: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY
por: Schreiber, S, et al.
Publicado: (2023)

International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients
por: Caron, Bénédicte, et al.
Publicado: (2023)

Early Intervention in Ulcerative Colitis: Ready for Prime Time?
por: Solitano, Virginia, et al.
Publicado: (2020)

Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis
por: Lichtenstein, Gary R., et al.
Publicado: (2015)

Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment
por: Sandborn, William J., et al.
Publicado: (2021)

Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis
por: Bencardino, Sarah, et al.
Publicado: (2023)

Treatment of Patients with Mild to Moderate Ulcerative Colitis: A Middle East Expert Consensus
por: Awadhi, Sameer Al, et al.
Publicado: (2023)

The role of upadacitinib in the treatment of moderate-to-severe active rheumatoid arthritis
por: Avci, Ali Berkant, et al.
Publicado: (2021)

Urgency as an Endpoint in Irritable Bowel Syndrome
por: Mangel, Allen W., et al.
Publicado: (2011)

Psychometric evaluation of the Urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis
por: Dubinsky, Marla C., et al.
Publicado: (2022)

Rectal Urgency Among Patients With Ulcerative Colitis or Crohn’s Disease: Analyses from a Global Survey
por: Ha, Christina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7j1e7qrgp85a69jp0lmkop45q7